Uncategories Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

October 02, 2021
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).

from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J


from TechCrunch https://ift.tt/2Y8UAKQ

About

This is dummy text. It is not meant to be read. Accordingly, it is difficult to figure out when to end it. But then, this is dummy text. It is not meant to be read. Period.

Next
« Prev Post
Previous
Next Post »
Subscribe to: Post Comments (Atom)